% | $
Quotes you view appear here for quick access.

Novartis AG Message Board

supermichaelcarbajal 2 posts  |  Last Activity: Feb 28, 2013 1:22 AM Member since: Jan 25, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • supermichaelcarbajal by supermichaelcarbajal Feb 28, 2013 1:22 AM Flag

    Roth Capital upped their price target on shares of TriMas Corp (NYSE: TRS) to $33.00 in a research note issued on Wednesday. The firm currently has a “buy” rating on the stock.
    TRS has been the subject of a number of other recent research reports. Analysts at Jefferies Group reiterated a “hold” rating on shares of TriMas Corp in a research note to investors on Wednesday. They now have a $33.00 price target on the stock, up previously from $29.00.
    Four research analysts have rated the stock with a buy rating, and one has assigned a hold rating to the company’s stock. TriMas Corp presently has a consensus rating of “buy” and an average target price of $32.00.
    Shares of TriMas Corp traded up 3.74% during mid-day trading on Wednesday, hitting $29.95. TriMas Corp has a one year low of $18.26 and a one year high of $32.13. The stock’s 50-day moving average is currently $30.2. The company has a market cap of $1.177 billion and a P/E ratio of 17.40.
    TriMas Corp last released its earnings data on Tuesday, February 26th. The company reported $0.33 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.33. The company had revenue of $301.00 million for the quarter, compared to the consensus estimate of $291.23 million. During the same quarter in the previous year, the company posted $0.25 earnings per share. The company’s revenue for the quarter was up 15.9% on a year-over-year basis. TriMas Corp has set its FY13 guidance at $2.15-2.25 EPS. Analysts expect that TriMas Corp will post $2.21 EPS for the current fiscal year.
    Trimas Corporation (Trimas) is a manufacturer and distributor of products for commercial, industrial and consumer markets.

    Source: Zolmax

    Sentiment: Strong Buy

  • FDA Approves Novartis' Gleevec For Children With Acute Lymphoblastic Leukemia

    Sentiment: Strong Buy

75.97-0.840(-1.09%)Apr 29 4:01 PMEDT